Beyond Amyloid: What’s in the Pipeline for Alzheimer’s?
Medscape
Last updated: June 15, 2026
Alzheimer's disease (AD) treatment is evolving beyond amyloid-targeting drugs, with a growing focus on multiple biological pathways. The current pipeline reflects a significant shift towards more precise and diversified therapeutic approaches, acknowledging the complex nature of AD.
- The development of anti-amyloid drugs has introduced disease-modifying treatments for early symptomatic AD, but their use remains limited. Research now encompasses tau pathology, neuroinflammation, immune dysfunction, metabolism, synaptic health, and vascular biology. Amyloid-targeting therapies now constitute only about 20% of agents in clinical development.
- Tau pathology is increasingly viewed as a potentially more clinically relevant target, as symptoms often correlate with tau accumulation and location. Promising tau-directed strategies include reducing tau production via antisense oligonucleotides and immunotherapies designed to clear pathologic tau.
- Neuroinflammation is now recognized as an active contributor to AD progression, not just a consequence of neurodegeneration. Therapies targeting the neuroimmune axis are a significant and rapidly growing segment of the AD drug pipeline. Strategies include activating TREM2, a microglial receptor, and inhibiting TNF, a potent inflammatory molecule.
